Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Among authors: schuler m. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR. Christoph DC, et al. Among authors: schuler m. J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff. J Thorac Oncol. 2013. PMID: 23242435 Free PMC article.
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
Wiesweg M, Ting S, Reis H, Worm K, Kasper S, Tewes M, Welt A, Richly H, Meiler J, Bauer S, Hense J, Gauler TC, Köhler J, Eberhardt WE, Darwiche K, Freitag L, Stamatis G, Breitenbücher F, Wohlschlaeger J, Theegarten D, Derks C, Cortes-Incio D, Linden G, Skottky S, Lütkes P, Dechêne A, Paul A, Markus P, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: schuler m. Eur J Cancer. 2013 Oct;49(15):3076-82. doi: 10.1016/j.ejca.2013.06.014. Epub 2013 Jul 19. Eur J Cancer. 2013. PMID: 23876834
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Welt A, Tewes M, Aktas B, O Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, Kimmig R, Schuler M, Kasper S. Welt A, et al. Among authors: schuler m. Breast Cancer Res Treat. 2013 Nov;142(1):81-8. doi: 10.1007/s10549-013-2718-4. Breast Cancer Res Treat. 2013. PMID: 24122392
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, Köhler J, Herold T, Schmid KW, Freitag L, Kasper S, Schuler M. Breitenbuecher F, et al. Among authors: schuler m. PLoS One. 2014 Jan 21;9(1):e85350. doi: 10.1371/journal.pone.0085350. eCollection 2014. PLoS One. 2014. PMID: 24465542 Free PMC article. Clinical Trial.
1,074 results